Table 1.
Baseline characteristics
| Variable | Overall | PWIDs | MSM | Other |
|---|---|---|---|---|
| Overall [n (%)] | 1874 (100) | 307 (16.4) | 892 (47.6) | 675 (36.0) |
| Sex [n (%)] | ||||
| Male | 1439 (76.8) | 196 (63.8) | 892 (100) | 351 (52.0) |
| Female | 435 (23.2) | 111 (36.2) | 0 (0.0) | 324 (48.0) |
| Age (years) at BL [median (IQR)] | 36.9 (15.2) | 31.7 (12.2) | 37.0 (13.4) | 37.7 (16.2) |
| Advanced fibrosis at BL [n (%)] according to | ||||
| Transient elastography >9.5 kPa | 19 (1.0) | 10 (3.3) | 6 (0.7) | 3 (0.4) |
| Missing values | 1694 (90.4) | 192 (62.5) | 846 (94.8) | 656 (97.2) |
| FIB4‐Score >3.25a | 88 (4.7) | 36 (11.7) | 26 (2.9) | 26 (3.9) |
| No fibrosis evaluation | 267 (14.2) | 40 (13.0) | 139 (15.6) | 88 (13.0) |
| HCV‐RNA at BL | ||||
| >12 IU/mL [n (%)] | 208 (11.1) | 166 (54.1) | 18 (2.0) | 24 (3.6) |
| Viral load (IU/mL) [median (IQR)] | 673 500 (3 671 930) | 113 500 (1 343 370) | 183 500 (2 302 490) | 530 500 (3 505 400) |
| HCV genotype [n (%b)] | ||||
| 1 | 122 (58.7) | 100 (60.2) | 12 (66.7) | 10 (16.7) |
| 2 | 5 (2.4) | 4 (2.4) | 1 (5.6) | 0 (0.0) |
| 3 | 39 (18.8) | 32 (19.3) | 1 (5.6) | 6 (12.5) |
| 4 | 18 (8.7) | 11 (6.6) | 4 (22.2) | 3 (4.2) |
| Unknown | 24 (11.5) | 19 (11.4) | 0 (0.0) | 5 (66.7) |
| ART [n (%)] | ||||
| No ART at BL, but later | 1802 (96.2) | 297 (96.7) | 850 (95.3) | 655 (97.0) |
| No ART at BL, never ART during FU | 60 (3.2) | 8 (2.6) | 33 (3.7) | 19 (2.8) |
| ART at baseline | 12 (0.6) | 2 (0.7) | 9 (1.0) | 1 (0.1) |
| HIV‐RNA at BL | ||||
| Viral load (log10/mL) [median (IQR)] | 4.8 (1.1) | 4.8 (1.3) | 4.9 (1.0) | 4.8 (1.1) |
| HIV‐RNA suppression (<1.7 log10/mL) [n (%)] | 290 (15.6) | 37 (12.1) | 145 (16.3) | 108 (16.0) |
| Missing values [n (%)] | 49 (2.6) | 4 (1.3) | 34 (3.8) | 11 (1.6) |
| CD4 count at BL (cells/µL) [median (IQR)] | 347 (369.0) | 400 (416.5) | 373 (356.0) | 327 (323.5) |
| Unknown [n (%)] | 40 (2.1) | 2 (0.7) | 27 (3.0) | 11 (1.6) |
| CDC stage at BL [n (%)] | ||||
| A1‐A3 | 1481 (79.0) | 236 (76.9) | 712 (80.0) | 533 (79.0) |
| B1‐B3 | 93 (5.0) | 15 (4.9) | 44 (5.0) | 34 (5.0) |
| C1‐C3 | 139 (7.4) | 26 (8.5) | 57 (6.4) | 56 (8.3) |
| AIDS | 433 (23.1) | 82 (26.7) | 179 (20.1) | 172 (25.5) |
| Unknown | 161 (8.6) | 30 (9.8) | 79 (8.9) | 52 (7.7) |
Abbreviations: AIDS, acquired immunodeficiency syndrome; ART, antiretroviral therapy; BL, baseline; CD4, cluster of differentiation 4; CDC, centers for disease control and prevention; FIB4‐Score, fibrosis‐4 score; FU, follow‐up; HCV, hepatitis C virus; HIV, human immunodeficiency virus; IQR, interquartile range; MSM, men who have sex with men; PWIDs, people with injection drug use; RNA, ribonucleic acid.
a
Applied upper limit of normal (ULN) for AST and ALT: 35 IU/L (females) and 50 IU/L (males).
b
Of HCV‐RNA at BL >12 IU/mL.